Infilea

Clobetasol Propionate, the active ingredient in Infilea, is a potent topical corticosteroid presented as a skin‑directed formulation for topical use. It is employed to manage inflammatory dermatoses such as psoriasis, eczema, dermatitis and lichen planus in adult patients. GNH USA supplies Infilea as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Clobetasol Propionate is a high‑potency corticosteroid used to treat inflammatory skin disorders. - Psoriasis: reduces plaque thickness and scaling by suppressing inflammation. - Eczema: alleviates itching and erythema through local immunosuppression. - Dermatitis: diminishes redness and swelling associated with contact or atopic dermatitis. - Lichen planus: controls lesions by decreasing immune‑mediated skin damage.

Topical application of clobetasol can produce local and systemic reactions, especially with prolonged use.

Common Side Effects: - Skin irritation or burning sensation at the application site. - Dryness or peeling of the treated skin. - Mild erythema or folliculitis. - Pruritus after withdrawal. - Telangiectasia in the treated area.

Serious or Rare Side Effects: - Atrophy of the epidermis or dermis leading to thinning skin. - Secondary bacterial, fungal or viral skin infections. - Hypopigmentation or depigmentation. - Systemic adrenal suppression with extensive use. - Allergic contact dermatitis to the formulation.

Clobetasol Propionate should be used according to clinical guidelines and prescriber instructions. - Duration of therapy: limit use to the shortest effective period to avoid skin atrophy. - Application area: avoid large surface areas, especially in children. - Occlusion: do not cover treated skin with airtight dressings unless directed. - Pre‑existing infections: treat bacterial, fungal or viral skin infections before initiating therapy. - Systemic absorption: monitor for signs of adrenal suppression with extensive or prolonged use. - Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Clobetasol Propionate may interact with other agents that affect skin integrity or systemic corticosteroid levels.

Major Interactions (Avoid):\n- Systemic corticosteroids: concurrent use can increase risk of systemic adrenal suppression. - Potent immunosuppressants (e.g., tacrolimus ointment): may enhance local immunosuppression and infection risk.

Moderate Interactions (Monitor Closely): - Antifungal or antibacterial topicals: monitor for reduced efficacy or increased irritation. - Skin‑lightening agents (hydroquinone): may increase risk of hypopigmentation. - Occlusive dressings: may raise systemic absorption, requiring observation.